Choroidal involution is a key component of oxygen-induced retinopathy

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 9, 2011, Pages 6238-6248

  Shao, Zhuo ^a,b   Dorfman, Allison L ^c   Seshadri, Swathi ^a   Djavari, Mikheil ^c   Kermorvant Duchemin, Elsa ^d   Sennlaub, Florian ^d   Blais, Martine ^a   Polosa, Anna ^c   Varma, Daya R ^b   Joyal, Jean Sébastien ^a,b   Lachapelle, Pierre ^c   Hardy, Pierre ^a   Sitaras, Nicholas ^a   Picard, Emilie ^a   Mancini, Joseph ^a,b   Sapieha, Przemyslaw ^e   Chemtob, Sylvain ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d SORBONNE UNIVERSITÉ   (France)

^e UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CIGLITAZONE; CYCLINE; GLUTATHIONE; IBUPROFEN; OXYGEN; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL DENSITY; CHOROIDAL INVOLUTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; ELECTRORETINOGRAPHY; ENDOTHELIUM CELL; ENZYME INHIBITION; EX VIVO STUDY; EXPLANT; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; IN VITRO STUDY; INVOLUTION; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PHOTORECEPTOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA BLOOD VESSEL; RETINA CONE; RETINA DEGENERATION; RETINA ISCHEMIA; RETROLENTAL FIBROPLASIA;

ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; CHOROID; CHOROID DISEASES; CORROSION CASTING; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; INFANT, NEWBORN; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, FLUORESCENCE; NIGHT VISION; OXYGEN; PHOTORECEPTOR CELLS, VERTEBRATE; PROSTAGLANDIN D2; RATS; RATS, SPRAGUE-DAWLEY; RETINOPATHY OF PREMATURITY;

EID: 80051504330     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6742     Document Type: Article

References (77)

1. Gilbert C, Foster A. Childhood blindness in the context of VISION 2020-the right to sight. Bull World Health Organ. 2001;79(3): 227-232.
2. van Heuven WA, Kiel JW. ROP surgery and ocular circulation. Eye. 2008;22(10):1267-1272.
3. Kermorvant-Duchemin E, Sapieha P, Sirinyan M, et al. Understanding ischemic retinopathies: emerging concepts from oxygen-induced retinopathy. Doc Ophthalmol. 2010;120(1):51-60.
4. Madan A, Penn JS. Animal models of oxygen-induced retinopathy. Front Biosci. 2003;8:1030-1043.
5. Chen ML, Guo L, Smith LE, Dammann CE, Dammann O. High or low oxygen saturation and severe retinopathy of prematurity: a meta-analysis. Pediatrics. 2010;125(6):1483-1492.
6. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007; 10(2):133-140.
7. Sapieha P, Hamel D, Shao Z, et al. Proliferative retinopathies: angiogenesis that blinds. Int J Biochem Cell Biol. 2010;42(1):5-12.
8. Fulton AB, Hansen RM, Moskowitz A, Barnaby AM. Multifocal ERG in subjects with a history of retinopathy of prematurity. Doc Ophthalmol. 2005;111(1):7-13.
9. Siatkowski RM, Dobson V, Quinn GE, Summers CG, Palmer EA, Tung B. Severe visual impairment in children with mild or moderate retinal residua following regressed threshold retinopathy of prematurity. J AAPOS. 2007;11(2):148-152.
10. Dobson V, Quinn GE, Abramov I, et al. Color vision measured with pseudoisochromatic plates at five-and-a-half years in eyes of children from the CRYO-ROP study. Invest Ophthalmol Vis Sci. 1996; 37(12):2467-2474.
11. Fulton AB, Hansen RM, Petersen RA, Vanderveen DK. The rod photoreceptors in retinopathy of prematurity: an electroretinographic study. Arch Ophthalmol. 2001;119(4):499-505.
12. Fulton AB, Hansen RM, Moskowitz A. Development of rod function in term born and former preterm subjects. Optom Vis Sci. 2009; 86(6):E653-E658.
13. Recchia FM, Recchia CC. Foveal dysplasia evident by optical coherence tomography in patients with a history of retinopathy of prematurity. Retina. 2007;27(9):1221-1226.
14. Soong GP, Shapiro M, Seiple W, Szlyk JP. Macular structure and vision of patients with macular heterotopia secondary to retinopathy of prematurity. Retina. 2008;28(8):1111-1116.
15. Baker PS, Tasman W. Optical coherence tomography imaging of the fovea in retinopathy of prematurity. Ophthalmic Surg Lasers Imaging. 2010;41(2):201-206.
16. Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res. 1994;36(6):724-731.
17. Berkowitz BA, Penn JS. Abnormal panretinal response pattern to carbogen inhalation in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1998;39(5):840-845.
18. Lachapelle P, Dembinska O, Rojas LM, Benoit J, Almazan G, Chemtob S. Persistent functional and structural retinal anomalies in newborn rats exposed to hyperoxia. Can J Physiol Pharmacol. 1999;77(1):48-55.
19. Dorfman AL, Polosa A, Joly S, Chemtob S, Lachapelle P. Functional and structural changes resulting from strain differences in the rat model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 1009;50(5):2436-2450.
20. Dorfman A, Cuenca N, Pinilla I, Chemtob S, Lachapelle P. Immunohistochemical evidence of synaptic retraction, cytoarchitectural remodelling and cell death in the inner retina of the rat model of OIR. Invest Ophthalmol Vis Sci. 2011;52:1693-1708.
21. Yu DY, Cringle SJ, Alder V, Su EN. Intraretinal oxygen distribution in the rat with graded systemic hyperoxia and hypercapnia. Invest Ophthalmol Vis Sci. 1999;40(9):2082-2087.
22. Hardy P, Nuyt AM, Abran D, St-Louis J, Varma DR, Chemtob S. Nitric oxide in retinal and choroidal blood flow autoregulation in newborn pigs: interactions with prostaglandins. Pediatr Res. 1996; 39(3):487-493.
23. Dumont I, Hardy P, Peri KG, et al. Regulation of endothelial nitric oxide synthase by PGD(2) in the developing choroid. Am J Physiol Heart Circ Physiol. 2000;278(1):H60-H66.
24. Hardy P, Peri KG, Lahaie I, Varma DR, Chemtob S. Increased nitric oxide synthesis and action preclude choroidal vasoconstriction to hyperoxia in newborn pigs. Circ Res. 1996;79(3):504-511.
25. Sharif NA, Davis TL, Williams GW. Ocular hypotensive DP-class prostaglandin receptor affinities determined by quantitative autoradiography on human eye sections. J Ocul Pharmacol Ther. 2005;21(2):121-132.
26. Sharif NA, Williams GW, Davis TL. Pharmacology and autoradiography of human DP prostanoid receptors using [(3)H]-BWA868C, a DP receptor-selective antagonist radioligand. Br J Pharmacol. 2000;131(6):1025-1038.
27. Hardy P, Dumont I, Bhattacharya M, et al. Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy. Cardiovasc Res. 2000;18 47(3):489-509.
28. Beauchamp MH, Sennlaub F, Speranza G, et al. Redox-dependent effects of nitric oxide on microvascular integrity in oxygen-induced retinopathy. Free Radic Biol Med. 2004;37(11):1885-1894.
29. Milne GL, Musiek ES, Morrow JD. The cyclopentenone (A2/J2) isoprostanes- unique, highly reactive products of arachidonate peroxidation. Antioxid Redox Signal. 2005;7(1-2):210-220.
30. Niki E. Lipid peroxidation: physiological levels and dual biological effects. Free Radic Biol Med. 2009;47(5):469-484.
31. Lee TS, Tsai HL, Chau LY. Induction of heme oxygenase-1 expression in murine macrophages is essential for the anti-inflammatory effect of low dose 15-deoxy-Delta 12,14-prostaglandin J2. J Biol Chem. 2003;278(21):19325-19330.
32. Landar A, Zmijewski JW, Dickinson DA, et al. Interaction of electrophilic lipid oxidation products with mitochondria in endothelial cells and formation of reactive oxygen species. Am J Physiol Heart Circ Physiol. 2006;290(5):H1777-H1787.
33. Oh JY, Giles N, Landar A, Darley-Usmar V. Accumulation of 15- deoxy-delta(12,14)-prostaglandin J2 adduct formation with Keap1 over time: effects on potency for intracellular antioxidant defence induction. Biochem J. 2008;411(2):297-306.
34. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med. 1999;6:698-701.
35. Chen Y, Morrow JD, Roberts LJ 2nd. Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. J Biol Chem. 1999;274(16):10863-10868.
36. Levonen AL, Dickinson DA, Moellering DR, Mulcahy RT, Forman HJ, Darley-Usmar VM. Biphasic effects of 15-deoxy-delta(12,14)- prostaglandin J(2) on glutathione induction and apoptosis in human endothelial cells. Arterioscler Thromb Vasc Biol. 2001; 21(11):1846-1851.
37. Erl W, Weber C, Zernecke A, et al. Cyclopentenone prostaglandins induce endothelial cell apoptosis independent of the peroxisome proliferator-activated receptor-gamma. Eur J Immunol. 2004; 34(1):241-250.
38. Geisen P, Peterson LJ, Martiniuk D, Uppal A, Saito Y, Hartnett ME. Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity. Mol Vis. 2008;14:345-357.
39. McColm JR, Geisen P, Hartnett ME. VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis. 2004;10:512-520.
40. Montezuma SR, Vavvas D, Miller JW. Review of the ocular angiogenesis animal models. Semin Ophthalmol. 2009;24(2):52-61.
41. Dorfman A, Dembinska O, Chemtob S, Lachapelle P. Early manifestations of postnatal hyperoxia on the retinal structure and function of the neonatal rat. Invest Ophthalmol Vis Sci. 2008; 49(1):458-466.
42. Browning J, Wylie CK, Gole G. Quantification of oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1997;38(6): 1168-1174.
43. Fei Y. Development of the cone photoreceptor mosaic in the mouse retina revealed by fluorescent cones in transgenic mice. Mol Vis. 2003; 15 (9):31-42.
44. Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci. 2001; 42(3):789-794.
45. Krucker T, Lang A, Meyer EP. New polyurethane-based material for vascular corrosion casting with improved physical and imaging characteristics. Microsc Res Tech. 2006;69(2):138-147.
46. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B. Doxorubicininduced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen: role of reactive oxygen and nitrogen species. J Biol Chem. 2000;275(43):33585-33592.
47. Hempel SL, Buettner GR, O'Malley YQ, Wessels DA, Flaherty DM. Dihydrofluorescein diacetate is superior for detecting intracellular oxidants: comparison with 2′,7′-dichlorodihydrofluorescein diacetate, 5(and 6)-carboxy-2′,7′-dichlorodihydrofluorescein diacetate, and dihydrorhodamine 123. Free Radic Biol Med. 1999;27(1-2): 146-159.
48. Sennlaub F, Valamanesh F, Vazquez-Tello A, et al. Cyclooxygenase- 2 in human and experimental ischemic proliferative retinopathy. Circulation. 2003;108(2):198-204.
49. Dembinska O, Rojas LM, Varma DR, Chemtob S, Lachapelle P. Graded contribution of retinal maturation to the development of oxygen-induced retinopathy in rats. Invest Ophthalmol Vis Sci. 2001; 42(5):1111-1118.
50. Hardy P, Beauchamp M, Sennlaub F, et al. Inflammatory lipid mediators in ischemic retinopathy. Pharmacol Rep. 2005; 57(suppl):169-190.
51. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferatoractivated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem. 1999;274(13):9116-9121.
52. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferatoractivated receptor gamma and promotes adipocyte differentiation. Cell. 1995;83(5):813-819.
53. Ates O, Alp HH, Caner I, et al. Oxidative DNA damage in retinopathy of prematurity. Eur J Ophthalmol. 2009;19(1):80-85.
54. Koh SH, Jung B, Song CW, Kim Y, Kim YS, Kim SH. 15-Deoxydelta12,14- prostaglandin J2, a neuroprotectant or a neurotoxicant? Toxicology. 2005;216(2-3):232-243.
55. Gayarre J, Avellano MI, Sanchez-Gomez FJ, Carrasco MJ, Canada FJ, Perez-Sala D. Modification of proteins by cyclopentenone prostaglandins is differentially modulated by GSH in vitro. Ann N Y Acad Sci. 2007; 1096:78-85.
56. Reisner DS, Hansen RM, Findl O, Petersen RA, Fulton AB. Darkadapted thresholds in children with histories of mild retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1997;38(6):1175-1183.
57. Fulton AB, Hansen RM, Moskowitz A, Akula JD. The neurovascular retina in retinopathy of prematurity. Prog Retin Eye Res. 2009; 28(6):452-482.
58. Saint-Geniez M, D'Amore PA. Development and pathology of the hyaloid, choroidal and retinal vasculature. Int J Dev Biol. 2004; 48(8-9):1045-1058.
59. Dreher Z, Robinson SR, Distler C. Muller cells in vascular and avascular retinae: a survey of seven mammals. J Comp Neurol. 1992;323(1):59-80.
60. Zhao S, Overbeek PA. Regulation of choroid development by the retinal pigment epithelium. Mol Vis. 2001; 7:277-282.
61. Sirinyan M, Sennlaub F, Dorfman A, et al. Hyperoxic exposure leads to nitrative stress and ensuing microvascular degeneration and diminished brain mass and function in the immature subject. Stroke. 2006; 37(11):2807-2815.
62. Beauchamp MH, Martinez-Bermudez AK, Gobeil F Jr, et al. Role of thromboxane in retinal microvascular degeneration in oxygeninduced retinopathy. J Appl Physiol. 2001;90(6):2279-2288.
63. Pfitzner J. Poiseuille and his law. Anaesthesia. 1976;31(2):273-275.
64. Pemp B, Schmetterer L. Ocular blood flow in diabetes and agerelated macular degeneration. Can J Ophthalmol. 2008;43(3):295-301.
65. Sharma J, Barr SM, Geng Y, Yun Y, Higgins RD. Ibuprofen improves oxygen-induced retinopathy in a mouse model. Curr Eye Res. 2003;27(5):309-314.
66. McLeod DS, Brownstein R, Lutty GA. Vaso-obliteration in the canine model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 1996;37(2):300-311.
67. Vrabec TR, McNamara JA, Eagle RC Jr, Tasman W. Cryotherapy for retinopathy of prematurity: a histopathologic comparison of a treated and untreated eye. Ophthalmic Surg. 1994;25(1):38-41.
68. Cao J, McLeod S, Merges CA, Lutty GA. Choriocapillaris degeneration and related pathologic changes in human diabetic eyes. Arch Ophthalmol. 1998;116(5):589-597.
69. Tsuji N, Matsuura T, Ozaki K, Sano T, Narama I. Diabetic retinopathy and choroidal angiopathy in diabetic rats (WBN/Kob). Exp Anim. 2009;58(5):481-487.
70. Musiek ES, Milne GL, McLaughlin B, Morrow JD. Cyclopentenone eicosanoids as mediators of neurodegeneration: a pathogenic mechanism of oxidative stress-mediated and cyclooxygenase-mediated neurotoxicity. Brain Pathol. 2005;15(2):149-158.
71. Kondo M, Oya-Ito T, Kumagai T, Osawa T, Uchida K. Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress. J Biol Chem. 2001;276(15):12076-12083.
72. Johnson L, Quinn GE, Abbasi S, Gerdes J, Bowen FW, Bhutani V. Severe retinopathy of prematurity in infants with birth weights less than 1250 grams: incidence and outcome of treatment with pharmacologic serum levels of vitamin E in addition to cryotherapy from 1985 to 1991. J Pediatr. 1995;127(4):632-639.
73. McLeod DS, Taomoto M, Otsuji T, Green WR, Sunness JS, Lutty GA. Quantifying changes in RPE and choroidal vasculature in eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2001;43(6):1986-1993.
74. Dorfman AL, Chemtob S, Lachapelle P. Postnatal hyperoxia and the developing rat retina: beyond the obvious vasculopathy. Doc Ophthalmol. 2010;120(1):61-66.
75. Fulton AB, Hansen RM. Photoreceptor function in infants and children with a history of mild retinopathy of prematurity. J Opt Soc Am A Opt Image Sci Vis. 1996;13(3):566-571.
76. Barnett JM, Yanni SE, Penn JS. The development of the rat model of retinopathy of prematurity. Doc Ophthalmol. 2010; 120(1):3-12.
77. Wallman J, Wildsoet C, Xu A, et al. Moving the retina: choroidal modulation of refractive state. Vision Res. 1995;35(1):37-50.